ICU sedation trial
15 Sep 2017
The intensive care unit at the Launceston General Hospital is in the top 25% of recruiting sites for an international multi-centre research trial that is evaluating ICU sedation management of patients who are on ventilators with an aim of improving function and recovery.
The study involves 63 ICUs throughout Australia and includes overseas sites in New Zealand, UK, Saudi Arabia and Malaysia. Once concluded, the trial will be the largest sedation randomised controlled trial (RCT) in critically ill patients ever conducted with a sample size of 4000 patients.
More than 50,000 critically ill patients in Australia undergo ventilation and sedation every year. The primary aim of this study is to determine whether Early-Goal-Directed Sedation, compared to standard care sedation, reduces 90-day mortality in critically ill patients who are expected to require mechanical ventilation for longer than 24 hours.
The trial will address many of the limitations of previous ICU sedation RCT’s and thus, its results will have a global impact and would change practice worldwide. If the trial demonstrates an improvement in one or more patient- centred outcomes, including mortality, cognitive function and/or health related quality of life, this would provide definitive evidence to clinicians and policymakers to guide the management of critically ill patients who require sedation following admission to the ICU.
Intensive Care Specialist Dr Matt Brain, LGH site investigator for the project, says it is vital that we continue to generate new evidence through research that will optimise treatments, improve standards of practice and ultimately improve outcomes for people who are admitted to the intensive care unit.
“Being part of national and international trials such as this project also provides an important platform to showcase LGH the has an active research culture which can potentially assist with the retention and recruitment of senior staff,” he said.
The Clifford Craig Foundation has provided research funding to support the project and enable local participation in the multi-centre trial.